yingweiwo

Ondansetron (GR 38032; SN 307; GR-C507/75)

Alias: GR 38032; SN 307; GR 38032F; GRC50775; GR-38032; SN-307; GR38032; SN307; GR-C507/75; trade name: Zofran
Cat No.:V0975 Purity: ≥98%
Ondansetron (GRC-50775; GR-38032; SN-307; GR38032; SN307; GR-C507/75; Zofran), an approved antiemetic drug, is a potent serotonin 5-HT3 receptor antagonist which is used to prevent nausea and vomiting caused by cancer chemotherapy, and radiation therapy.
Ondansetron (GR 38032; SN 307; GR-C507/75)
Ondansetron (GR 38032; SN 307; GR-C507/75) Chemical Structure CAS No.: 99614-02-5
Product category: 5-HT Receptor
This product is for research use only, not for human use. We do not sell to patients.
Size Price Stock Qty
50mg
100mg
250mg
500mg
1g
2g
5g
10g
Other Sizes

Other Forms of Ondansetron (GR 38032; SN 307; GR-C507/75):

  • Ondansetron hydrochloride dihydrate (ondansetron hydrochloride dihydrate; GR 38032 hydrochloride dihydrate; SN 307 hydrochloride dihydrate)
  • Ondansetron-d5 (GR 38032-d5; SN 307-d5)
  • Ondansetron HCl (GR 38032; SN 307; GR-C507/75)
  • Ondansetron-d3 (GR 38032-d3; SN 307-d3)
  • Ondansetron-13C,d3
Official Supplier of:
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Top Publications Citing lnvivochem Products
Purity & Quality Control Documentation

Purity: ≥98%

Product Description

Ondansetron (GRC-50775; GR-38032; SN-307; GR38032; SN307; GR-C507/75; Zofran), an approved antiemetic drug, is a potent serotonin 5-HT3 receptor antagonist which is used to prevent nausea and vomiting caused by cancer chemotherapy, and radiation therapy. Ondansetron, a 5-HT3A receptor antagonist, reversibly inhibited the 5-HT (30 microM) signal by 70% at 0.3 nM and completely eliminated the response at 3 nM. The study found that auditory gating improved with 0.33 and 1 mg/kg, IP, but not with the lowest tested acute ondansetron dose of 0.1 mg/kg.

Biological Activity I Assay Protocols (From Reference)
Targets
5-HT3
ln Vivo
Ondansetron (GR 38032; SN 307) (2.4-6 mg/kg; intraperitoneal injection; six times in 15 days) has a TD50 value of 3.7±0.6 mg/kg and an LD50 of 4.6±0.5 mg/kg in mice [4]. Ondansetron (8 mg/kg; intraperitoneal injection; once) combined with olanzapine has a good effect in preventing CINV in patients with NSCLC, especially for advanced patients [7]. Ondansetron (2 mg/kg; intraperitoneal injection; six consecutive days) Animal model: NSCLC patients receiving chemotherapy [7] Dosage: 8 mg Administration method: intraperitoneal injection (ip) Results: showed TD50 and LD50 doses of 3.7± 0.6 mg) exhibits anti-inflammatory effects through 5-HT3 receptors [8]. They are 4.6±0.5 mg/kg and 4.6±0.5 mg/kg respectively. Animal model: Male Swiss mice with colitis [8] Dosage: 2 mg/kg Administration: intraperitoneal injection (ip) Results: Demonstrated MPO activity and tumor necrosis factor-α, interleukin-6 and leukocyte-interleukin 1β was significantly reduced.
Animal Protocol
NSCLC Patients Treated With Chemotherapy
8 mg
Intraperitoneal Injection (i.p.)
ADME/Pharmacokinetics
Absorption, Distribution and Excretion
Ondansetron is absorbed from the gastrointestinal tract and undergoes some limited first-pass metabolism. Mean bioavailability in healthy subjects, following administration of a single 8-mg tablet, was recorded as being approximately 56% to 60%. Bioavailability is also slightly enhanced by the presence of food. Ondansetron systemic exposure does not increase proportionately to dose. The AUC from a 16-mg tablet was 24% greater than predicted from an 8-mg tablet dose. This may reflect some reduction of first-pass metabolism at higher oral doses.
Following oral or IV administration, ondansetron is extensively metabolised and excreted in the urine and faeces.
The volume of distribution of ondansetron has been recorded as being approximately 160L.
The clearance values determined for ondansetron in various patient age groups were recorded as approximately 0.38 L/h/kg in normal adult volunteers aged 19-40 yrs, 0.32 L/h/kg in normal adult volunteers aged 61-74 yrs, 0.26 L/h/kg in normal adult volunteers aged >=75 yrs.
Ondansetron is a 5-HT3 receptor antagonist that is an effective anti-emetic in cats. The purpose of this study was to evaluate the pharmacokinetics of ondansetron in healthy cats. Six cats with normal complete blood count, serum biochemistry, and urinalysis received 2 mg oral (mean 0.43 mg/kg), subcutaneous (mean 0.4 mg/kg), and intravenous (mean 0.4 mg/kg) ondansetron in a cross-over manner with a 5-day wash out. Serum was collected prior to, and at 0.25, 0.5, 1, 2, 4, 8, 12, 18, and 24 hr after administration of ondansetron. Ondansetron concentrations were measured using liquid chromatography coupled to tandem mass spectrometry. Noncompartmental pharmacokinetic modeling and dose interval modeling were performed. Repeated measures anova was used to compare parameters between administration routes. Bioavailability of ondansetron was 32% (oral) and 75% (subcutaneous). Calculated elimination half-life of ondansetron was 1.84 + or - 0.58 hr (intravenous), 1.18 + or - 0.27 hr (oral) and 3.17 + or - 0.53 hr (subcutaneous). The calculated elimination half-life of subcutaneous ondansetron was significantly longer (P < 0.05) than oral or intravenous administration. Subcutaneous administration of ondansetron to healthy cats is more bioavailable and results in a more prolonged exposure than oral administration. This information will aid management of emesis in feline patients.
Nausea and vomiting are some of the major side effects caused by certain drug therapies, e.g. chemotherapy, radiotherapy and general anesthesia. Because of the nature of the symptoms, oral delivery is inappropriate, while intravenous administration may be unpractical. The aim of the present study was to develop a transdermal gel (2% Klucel) for ondansetron, a first line 5-HT3-receptor-antagonist antiemetic. The effects of the penetration enhancer camphor and isopropyl-myristate (IPM) were first investigated in-vitro using modified Franz diffusion-cells and then tested in-vivo in a rabbit model by measuring skin and plasma concentrations. Since a disadvantage of transdermal delivery is a prolonged lag-time, the effect of skin treatment with a micro-needle roller was tested. The in-vitro permeation studies through excised porcine ear skin showed that the presence of 2.5% camphor or IPM increased steady state flux by 1.2- and 2.5-fold, respectively, compared to the control gel. Ondansetron was not detectable in either skin or plasma following in-vivo application of the base-gel, whereas the camphor gel and IPM gel delivered 20 and 81 ug/sq cm of ondansetron, respectively. Microporation led to an increase in plasma Cmax and AUC by 10.47 + or - 1.68-fold and 9.31 + or - 4.91-fold, respectively, for the camphor gel, and by 2.31 + or -0.53-fold and 1.59 + or - 0.38-fold, respectively for the IPM gel. In conclusion, the 2.5% IPM gel demonstrated optimal in-vivo transdermal flux. Skin pretreatment with a micro-needle roller slightly improved the delivery of the IPM gel, whereas dramatically increased the transdermal delivery of the camphor gel.
Ondansetron is a potent antiemetic drug that has been commonly used to treat acute and chemotherapy-induced nausea and vomiting (CINV) in dogs. The aim of this study was to perform a pharmacokinetic analysis of ondansetron in dogs following oral administration of a single dose. A single 8-mg oral dose of ondansetron was administered to beagles (n = 18), and the plasma concentrations of ondansetron were measured by liquid chromatography-tandem mass spectrometry. The data were analyzed by modeling approaches using ADAPT5, and model discrimination was determined by the likelihood-ratio test. The peak plasma concentration (Cmax ) was 11.5 +/- 10.0 ng/mL at 1.1 +/- 0.8 hr. The area under the plasma concentration vs. time curve from time zero to the last measurable concentration was 15.9 +/- 14.7 ng hr/mL, and the half-life calculated from the terminal phase was 1.3 +/- 0.7 hr. The interindividual variability of the pharmacokinetic parameters was high (coefficient of variation > 44.1%), and the one-compartment model described the pharmacokinetics of ondansetron well. The estimated plasma concentration range of the usual empirical dose from the Monte Carlo simulation was 0.1-13.2 ng/mL. These findings will facilitate determination of the optimal dose regimen for dogs with CINV.
Ondansetron is the drug of choice to prevent nausea in women undergoing cesarean surgery and can be used to prevent neonatal abstinence syndrome (NAS). The pharmacokinetics of ondansetron have not been characterized in pregnant women or in newborns. A nonlinear mixed-effects modeling approach was used to analyze plasma samples obtained from 20 nonpregnant and 40 pregnant women following a single administration of 4 or 8 mg ondansetron, from umbilical cord blood at delivery, and from neonates after birth. The analysis indicates that: ondansetron disposition is not affected by pregnancy (P > 0.05), but influenced by dose (P < 0.05), and is characterized by rapid transplacental transfer and longer elimination half-life in neonates compared to their mother. A dosing regimen for prevention of NAS was designed based on the model. The regimen involves IV administration of 4 mg to the mothers shortly before cord clamping, or oral administration of 0.07 mg/kg (or equivalently 0.04 mg/kg IV) to neonates.
For more Absorption, Distribution and Excretion (Complete) data for Ondansetron (8 total), please visit the HSDB record page.
Metabolism / Metabolites
In vitro metabolism studies have shown that ondansetron is a substrate for human hepatic cytochrome P450 enzymes, including CYP1A2, CYP2D6 and CYP3A4. In terms of overall ondansetron turnover, CYP3A4 played the predominant role. Because of the multiplicity of metabolic enzymes capable of metabolizing ondansetron, it is likely that inhibition or loss of one enzyme (e.g. CYP2D6 enzyme deficiency) will be compensated by others and may result in little change in overall rates of ondansetron clearance. Following oral or IV administration, ondansetron is extensively metabolised and excreted in the urine and faeces. In humans, less than 10% of the dose is excreted unchanged in the urine. The major urinary metabolites are glucuronide conjugates (45%), sulphate conjugates (20%) and hydroxylation products (10%). The primary metabolic pathway is subsequently hydroxylation on the indole ring followed by subsequent glucuronide or sulfate conjugation. Although some nonconjugated metabolites have pharmacologic activity, these are not found in plasma at concentrations likely to significantly contribute to the biological activity of ondansetron.
Ondansetron is extensively metabolized in humans, with approximately 5% of a radiolabeled dose recovered as the parent compound from the urine. The primary metabolic pathway is hydroxylation on the indole ring followed by subsequent glucuronide or sulfate conjugation. Although some nonconjugated metabolites have pharmacologic activity, these are not found in plasma at concentrations likely to significantly contribute to the biological activity of ondansetron.
Ondansetron has known human metabolites that include 6-hydroxy-ondansetron, 7-hydroxy-ondansetron, and 8-hydroxy-ondansetron.
Hepatic
Half Life: 5.7 hours
Biological Half-Life
The half-life of ondansetron after either an 8 mg oral dose or intravenous dose was approximately 3-4 hours and could be extended to 6-8 hours in the elderly.
In humans ... elimination half lives are approximately 3-4 hours, but are prolonged in elderly patients.
... Six cats with normal complete blood count, serum biochemistry, and urinalysis received 2 mg oral (mean 0.43 mg/kg), subcutaneous (mean 0.4 mg/kg), and intravenous (mean 0.4 mg/kg) ondansetron in a cross-over manner with a 5-day wash out. Serum was collected prior to, and at 0.25, 0.5, 1, 2, 4, 8, 12, 18, and 24 hr after administration of ondansetron. ... Calculated elimination half-life of ondansetron was 1.84 + or - 0.58 hr (intravenous), 1.18 + or - 0.27 hr (oral) and 3.17 + or - 0.53 hr (subcutaneous). The calculated elimination half-life of subcutaneous ondansetron was significantly longer (P < 0.05) than oral or intravenous administration. ...
... A single 8-mg oral dose of ondansetron was administered to beagles (n = 18), ... and the half-life calculated from the terminal phase was 1.3 +/- 0.7 hr. ...
Toxicity/Toxicokinetics
Toxicity Summary
IDENTIFICATION AND USE: Ondansetron forms as crystals from methanol. It is a drug used for the prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy in both human and veterinary cases. Prolongation of the QT interval and cases of torsades de pointes have been reported in patients receiving ondansetron. Liver failure and death have been reported rarely in patients with cancer receiving ondansetron concomitantly with other drugs, including potentially hepatotoxic cytotoxic chemotherapy and antibiotics. Ondansetron hydrochloride may cause a serious anaphylactic reaction. In a study of children whose mothers received promethazine or ondansetron during pregnancy, no clinically significant adverse neurobehavioral effects or obstetric outcomes were identified. According to a different study, the teratogenic risk with ondansetron is low but an increased risk for a cardiac septum defect is likely. There was also no evidence of damage to genetic material noted in in vitro chromosome aberration tests using human peripheral lymphocytes. ANIMAL STUDIES: Ondansetron was administered orally to rats at doses of 1, 4, and 15 mg/kg during gametogenesis, mating, pregnancy, and lactation periods. It is proposed that the maximum noneffective dose of ondansetron was 4 and 15 mg/kg with respect to general toxicity and reproductive capacity in F0 animals respectively. The maximum noneffective dose with respect to development in F1 and F2 animals was suggested to be 15 mg/kg. After IV administration of 0.5, 1.5, and 4 mg/kg of ondansetron daily during gestation and lactation period, the results suggest that the maximum noneffective dose of ondansetron for general toxicity in dams was 1.5 mg/kg and that for reproduction toxicity in dams and developmental toxicity in fetuses and offspring was 4 mg/kg. A slight maternal toxicity was observed at the highest dose level in intravenous organogenesis (4.0 mg/kg/day) studies in the rabbit. Effects included maternal body weight loss and increased incidence of early fetal death. There was no evidence of damage to genetic material noted in in vitro V-79 mammalian cell mutation studies or in vivo chromosome aberration assays in mouse bone marrow. No evidence of mutagenicity was observed in microbial mutagen tests using mutant strains of Salmonella typhimurium, Escherichia coli or Saccharomyces cerevisiae, with or without a rat liver post-mitochondrial metabolizing system. Carcinogenic effects were not seen in 2-year studies in rats and mice with oral ondansetron doses up to 10 and 30 mg/kg/day, respectively.
Ondansetron is a selective serotonin 5-HT3 receptor antagonist. The antiemetic activity of the drug is brought about through the inhibition of 5-HT3 receptors present both centrally (medullary chemoreceptor zone) and peripherally (GI tract). This inhibition of 5-HT3 receptors in turn inhibits the visceral afferent stimulation of the vomiting center, likely indirectly at the level of the area postrema, as well as through direct inhibition of serotonin activity within the area postrema and the chemoreceptor trigger zone.
Interactions
The nephrotoxicity limits the clinical application of cisplatin. Human organic cation transporter 2 (OCT2) and multidrug and toxin extrusion proteins (MATEs) work in concert in the elimination of cationic drugs such as cisplatin from the kidney. We hypothesized that co-administration of ondansetron would have an effect on cisplatin nephrotoxicity by altering the function of cisplatin transporters. The inhibitory potencies of ondansetron on metformin accumulation mediated by OCT2 and MATEs were determined in the stable HEK-293 cells expressing these transporters. The effects of ondansetron on drug disposition in vivo were examined by conducting the pharmacokinetics of metformin, a classical substrate for OCTs and MATEs, in wild-type and Mate1-/- mice. The nephrotoxicity was assessed in the wild-type and Mate1-/- mice received cisplatin with and without ondansetron. Both MATEs, including human MATE1, human MATE2-K, and mouse Mate1, and OCT2 (human and mouse) were subject to ondansetron inhibition, with much greater potencies by ondansetron on MATEs. Ondansetron significantly increased tissue accumulation and pharmacokinetic exposure of metformin in wild-type but not in Mate1-/- mice. Moreover, ondansetron treatment significantly enhanced renal accumulation of cisplatin and cisplatin-induced nephrotoxicity which were indicated by increased levels of biochemical and molecular biomarkers and more severe pathohistological changes in mice. Similar increases in nephrotoxicity were caused by genetic deficiency of MATE function in mice. Therefore, the potent inhibition of MATEs by ondansetron enhances the nephrotoxicity associated with cisplatin treatment in mice. Potential nephrotoxic effects of combining the chemotherapeutic cisplatin and the antiemetic 5-hydroxytryptamine-3 (5-HT3) receptor antagonists, such as ondansetron, should be investigated in patients.
Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small trials indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.
Serotonin syndrome (including altered mental status, autonomic instability, and neuromuscular abnormalities) has been described following the concomitant use of 5-HT3 receptor antagonists and other serotonergic drugs, including selective serotonin reuptake inhibitors (SSRIs) and serotonin and noradrenaline reuptake inhibitors.
In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.
For more Interactions (Complete) data for Ondansetron (8 total), please visit the HSDB record page.
Non-Human Toxicity Values
LD50 Rat IV 15-20 mg/kg
LD50 Rat oral 100-150 mg/kg
LD50 Mouse IV 1.0-2.5 mg/kg
LD50 Mouse oral 10-30 mg/kg
References

[1]. Ion permeation and conduction in a human recombinant 5-HT3 receptor subunit (h5-HT3A). J Physiol. 1998 Mar 15;507 ( Pt 3):653-65.

[2]. Recombinant human 5-HT3A receptors in outside-out patches of HEK 293 cells: basic properties and barbiturate effects. Naunyn Schmiedebergs Arch Pharmacol. 2000 Sep;362(3):255-65.

[3]. Ondansetron results in improved auditory gating in DBA/2 mice through a cholinergic mechanism. Brain Res. 2009 Dec 1;1300:41-50.

[4]. Circadian rhythms in toxic effects of the serotonin antagonist ondansetron in mice. Chronobiol Int. 2003 Nov;20(6):1103-16.

[5]. The 5-HT3 receptor antagonist, ondansetron, blocks the development and expression of ethanol-induced locomotor sensitization in mice. Behav Pharmacol. 2009 Feb;20(1):78-83.

[6]. Cardiac safety concerns for ondansetron, an antiemetic commonly used for nausea linked to cancer treatment and following anaesthesia. Expert Opin Drug Saf. 2013 May;12(3):421-31.

[7]. Effectiveness of Olanzapine Combined with Ondansetron in Prevention of Chemotherapy-Induced Nausea and Vomiting of Non-small Cell Lung Cancer. Cell Biochem Biophys. 2015 Jun;72(2):471-3.

[8]. Anti-inflammatory effect of ondansetron through 5-HT3 receptors on TNBS-induced colitis in rat. EXCLI J2012 Feb 22:11:30-44. eCollection 2012.

Additional Infomation
Therapeutic Uses
/CLINICAL TRIALS/ ClinicalTrials.gov is a registry and results database of publicly and privately supported clinical studies of human participants conducted around the world. The Web site is maintained by the National Library of Medicine (NLM) and the National Institutes of Health (NIH). Each ClinicalTrials.gov record presents summary information about a study protocol and includes the following: Disease or condition; Intervention (for example, the medical product, behavior, or procedure being studied); Title, description, and design of the study; Requirements for participation (eligibility criteria); Locations where the study is being conducted; Contact information for the study locations; and Links to relevant information on other health Web sites, such as NLM's MedlinePlus for patient health information and PubMed for citations and abstracts for scholarly articles in the field of medicine. Ondansetron is included in the database.
Prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin ... . /Included in US product label/
Prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy. /Included in US product label/
Prevention of nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen. /Included in US product label/
For more Therapeutic Uses (Complete) data for Ondansetron (7 total), please visit the HSDB record page.
Drug Warnings
Because of the risk of QT-interval prolongation, ondansetron should be avoided in patients with congenital long QT syndrome. ECG monitoring is recommended in patients with electrolyte abnormalities such as hypokalemia or hypomagnesemia, congestive heart failure, or bradyarrhythmias and in those receiving other drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected prior to IV administration of ondansetron. Because effects of ondansetron on the QT interval are dose related, use of single IV doses exceeding 16 mg should be avoided. Patients receiving ondansetron should be advised to seek immediate medical care if feelings of faintness, lightheadedness, irregular heartbeat, shortness of breath, or dizziness occur.
Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, concomitant use of apomorphine with ondansetron is contraindicated
Advise patients of the possibility of serotonin syndrome with concomitant use of Zofran and another serotonergic agent such as medications to treat depression and migraines. Advise patients to seek immediate medical attention if the following symptoms occur: changes in mental status, autonomic instability, neuromuscular symptoms with or without gastrointestinal symptoms.
Seizures (including tonic-clonic seizures) have been reported rarely in patients receiving ondansetron.
For more Drug Warnings (Complete) data for Ondansetron (32 total), please visit the HSDB record page.
Pharmacodynamics
Ondansetron is a highly specific and selective serotonin 5-HT3 receptor antagonist, not shown to have activity at other known serotonin receptors and with low affinity for dopamine receptors,. The serotonin 5-HT3 receptors are located on the nerve terminals of the vagus in the periphery, and centrally in the chemoreceptor trigger zone of the area postrema,. The temporal relationship between the emetogenic action of emetogenic drugs and the release of serotonin, as well as the efficacy of antiemetic agents, suggest that chemotherapeutic agents release serotonin from the enterochromaffin cells of the small intestine by causing degenerative changes in the GI tract,. The serotonin then stimulates the vagal and splanchnic nerve receptors that project to the medullary vomiting center, as well as the 5-HT3 receptors in the area postrema, thus initiating the vomiting reflex, causing nausea and vomiting,. Moreover, the effect of ondansetron on the QTc interval was evaluated in a double-blind, randomized, placebo and positive (moxifloxacin) controlled, crossover study in 58 healthy adult men and women. Ondansetron was tested at single doses of 8 mg and 32 mg infused intravenously over 15 minutes. At the highest tested dose of 32 mg, prolongation of the Fridericia-corrected QTc interval (QT/RR0.33=QTcF) was observed from 15 min to 4 h after the start of the 15 min infusion, with a maximum mean (upper limit of 90% CI) difference in QTcF from placebo after baseline-correction of 19.6 (21.5) msec at 20 min. At the lower tested dose of 8 mg, QTc prolongation was observed from 15 min to 1 h after the start of the 15-minute infusion, with a maximum mean (upper limit of 90% CI) difference in QTcF from placebo after baseline-correction of 5.8 (7.8) msec at 15 min. The magnitude of QTc prolongation with ondansetron is expected to be greater if the infusion rate is faster than 15 minutes. The 32 mg intravenous dose of ondansetron must not be administered. No treatment-related effects on the QRS duration or the PR interval were observed at either the 8 or 32 mg dose. An ECG assessment study has not been performed for orally administered ondansetron. On the basis of pharmacokinetic-pharmacodynamic modelling, an 8 mg oral dose of ondansetron is predicted to cause a mean QTcF increase of 0.7 ms (90% CI -2.1, 3.3) at steady-state, assuming a mean maximal plasma concentration of 24.7 ng/mL (95% CI 21.1, 29.0). The magnitude of QTc prolongation at the recommended 5 mg/m2 dose in pediatrics has not been studied, but pharmacokinetic-pharmacodynamic modeling predicts a mean increase of 6.6 ms (90% CI 2.8, 10.7) at maximal plasma concentrations. In healthy subjects, single intravenous doses of 0.15 mg/kg of ondansetron had no effect on esophageal motility, gastric motility, lower esophageal sphincter pressure, or small intestinal transit time. Multiday administration of ondansetron has been shown to slow colonic transit in healthy subjects. Ondansetron has no effect on plasma prolactin concentrations.
These protocols are for reference only. InvivoChem does not independently validate these methods.
Physicochemical Properties
Molecular Formula
C18H19N3O
Molecular Weight
293.36
Exact Mass
293.152
Elemental Analysis
C, 73.69; H, 6.53; N, 14.32; O, 5.45
CAS #
99614-02-5
Related CAS #
Ondansetron hydrochloride dihydrate; 103639-04-9; Ondansetron-d5; 1219798-86-3; Ondansetron hydrochloride; 99614-01-4; Ondansetron-d3; 1132757-82-4; Ondansetron-13C,d3; 2699607-85-5
PubChem CID
4595
Appearance
White to off-white solid powder
Density
1.3±0.1 g/cm3
Boiling Point
546.0±30.0 °C at 760 mmHg
Melting Point
231 - 232ºC
Flash Point
284.0±24.6 °C
Vapour Pressure
0.0±1.5 mmHg at 25°C
Index of Refraction
1.678
LogP
2.07
Hydrogen Bond Donor Count
0
Hydrogen Bond Acceptor Count
2
Rotatable Bond Count
2
Heavy Atom Count
22
Complexity
440
Defined Atom Stereocenter Count
0
SMILES
O=C1C2C3=C([H])C([H])=C([H])C([H])=C3N(C([H])([H])[H])C=2C([H])([H])C([H])([H])C1([H])C([H])([H])N1C([H])=C([H])N=C1C([H])([H])[H]
InChi Key
FELGMEQIXOGIFQ-UHFFFAOYSA-N
InChi Code
InChI=1S/C18H19N3O/c1-12-19-9-10-21(12)11-13-7-8-16-17(18(13)22)14-5-3-4-6-15(14)20(16)2/h3-6,9-10,13H,7-8,11H2,1-2H3
Chemical Name
9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one
Synonyms
GR 38032; SN 307; GR 38032F; GRC50775; GR-38032; SN-307; GR38032; SN307; GR-C507/75; trade name: Zofran
HS Tariff Code
2934.99.9001
Storage

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Note: This product requires protection from light (avoid light exposure) during transportation and storage.
Shipping Condition
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
Solubility Data
Solubility (In Vitro)
DMSO: 0.1~10 mg/mL (0.3~34.1 mM)
Water: <1 mg/mL
Ethanol: <1 mg/mL
Solubility (In Vivo)
Solubility in Formulation 1: ≥ 1 mg/mL (3.41 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear DMSO stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.

Solubility in Formulation 2: 1 mg/mL (3.41 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.

View More

Solubility in Formulation 3: ≥ 1 mg/mL (3.41 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.


 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 3.4088 mL 17.0439 mL 34.0878 mL
5 mM 0.6818 mL 3.4088 mL 6.8176 mL
10 mM 0.3409 mL 1.7044 mL 3.4088 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.

Calculator

Molarity Calculator allows you to calculate the mass, volume, and/or concentration required for a solution, as detailed below:

  • Calculate the Mass of a compound required to prepare a solution of known volume and concentration
  • Calculate the Volume of solution required to dissolve a compound of known mass to a desired concentration
  • Calculate the Concentration of a solution resulting from a known mass of compound in a specific volume
An example of molarity calculation using the molarity calculator is shown below:
What is the mass of compound required to make a 10 mM stock solution in 5 ml of DMSO given that the molecular weight of the compound is 350.26 g/mol?
  • Enter 350.26 in the Molecular Weight (MW) box
  • Enter 10 in the Concentration box and choose the correct unit (mM)
  • Enter 5 in the Volume box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 17.513 mg appears in the Mass box. In a similar way, you may calculate the volume and concentration.

Dilution Calculator allows you to calculate how to dilute a stock solution of known concentrations. For example, you may Enter C1, C2 & V2 to calculate V1, as detailed below:

What volume of a given 10 mM stock solution is required to make 25 ml of a 25 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=25 μM, V2=25 ml and V1 is the unknown:
  • Enter 10 into the Concentration (Start) box and choose the correct unit (mM)
  • Enter 25 into the Concentration (End) box and select the correct unit (mM)
  • Enter 25 into the Volume (End) box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 62.5 μL (0.1 ml) appears in the Volume (Start) box
g/mol

Molecular Weight Calculator allows you to calculate the molar mass and elemental composition of a compound, as detailed below:

Note: Chemical formula is case sensitive: C12H18N3O4  c12h18n3o4
Instructions to calculate molar mass (molecular weight) of a chemical compound:
  • To calculate molar mass of a chemical compound, please enter the chemical/molecular formula and click the “Calculate’ button.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
  • Molecular mass (or molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
  • Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
/

Reconstitution Calculator allows you to calculate the volume of solvent required to reconstitute your vial.

  • Enter the mass of the reagent and the desired reconstitution concentration as well as the correct units
  • Click the “Calculate” button
  • The answer appears in the Volume (to add to vial) box
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal to make allowance for loss during the experiment)
Step 2: Enter in vivo formulation (This is only a calculator, not the exact formulation for a specific product. Please contact us first if there is no in vivo formulation in the solubility section.)
+
+
+

Calculation results

Working concentration mg/mL;

Method for preparing DMSO stock solution mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.

Method for preparing in vivo formulation:Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.

(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
             (2) Be sure to add the solvent(s) in order.

Clinical Trial Information
Ondansetron and Gabapentin in Preventing Postoperative Nausea and Vomiting After Laparoscopic Sleeve Gastrectomy
CTID: NCT05620641
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-11-27
Ondansetron for the Management of Atrial Fibrillation
CTID: NCT05844501
Phase: Phase 4    Status: Recruiting
Date: 2024-11-26
Role of Prophylactic Antiemetics in Women Receiving Intrathecal Morphine and Lipophilic Opioids Added to Bupivacaine for Cesarean Section
CTID: NCT06704139
Phase: Phase 4    Status: Not yet recruiting
Date: 2024-11-25
Cisplatin Disposition and Kidney Injury
CTID: NCT03817970
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-11-21
Aprepitant and Ondansetron Monotherapy or Combination for Postoperative Nausea and Vomiting in Thyroid Cancer
CTID: NCT06697782
Phase: N/A    Status: Not yet recruiting
Date: 2024-11-20
View More

Antiemetic Fosaprepitant To Remedy Nausea and Vomiting
CTID: NCT06382012
Phase: Phase 2/Phase 3    Status: Recruiting
Date: 2024-11-12


Multimodal Analgesia Effect on Post Surgical Patient
CTID: NCT04240626
Phase: Phase 4    Status: Recruiting
Date: 2024-11-08
Intraoperative Acupoint Stimulation to Prevent Post-Operative Nausea and Vomiting (PONV)
CTID: NCT02473042
Phase: N/A    Status: Active, not recruiting
Date: 2024-10-16
Inhaled Isopropyl Alcohol for Treatment of Nausea
CTID: NCT05418244
Phase: Phase 2/Phase 3    Status: Recruiting
Date: 2024-10-09
Recommendations of Enhanced Recovery Interventions for Patient's Clinical Team and Collection of Associated Data
CTID: NCT04606264
Phase: Phase 3    Status: Recruiting
Date: 2024-10-08
BMT-08: A Comparative Effectiveness Study of Transdermal Granisetron to Ondansetron
CTID: NCT04150614
Phase: Phase 4    Status: Recruiting
Date: 2024-09-19
Multi-DOSE Oral Ondansetron for Pediatric Acute GastroEnteritis
CTID: NCT03851835
Phase: Phase 3    Status: Completed
Date: 2024-09-19
Ondansetron HCl Orally Disintegrating Tablets Under Non-Fasting Conditions
CTID: NCT00934921
Phase: Phase 1    Status: Completed
Date: 2024-08-21
Ondansetron HCl Orally Disintegrating Tablets Under Fasting Conditions
CTID: NCT00934180
Phase: Phase 1    Status: Completed
Date: 2024-08-21
Ondansetron Use for Preventing Pruritus In Patients Undergoing Cesarean Section
CTID: NCT06297499
Phase: Phase 1    Status: Not yet recruiting
Date: 2024-07-29
Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
CTID: NCT03511118
Phase:    Status: Recruiting
Date: 2024-07-24
A Trial of HRS5580 in Prevention of Postoperative Nausea and Vomiting of Adults
CTID: NCT06475846
Phase: Phase 2    Status: Not yet recruiting
Date: 2024-06-26
Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients
CTID: NCT04503668
Phase: Phase 3    Status: Terminated
Date: 2024-06-10
Comparative Study Between Intravenous Granisetron and Ondansetron on Their Effect on Hemodynamics and Shivering After Spinal Anesthesia in Elective Cesarean Delivery
CTID: NCT06437236
Phase: N/A    Status: Recruiting
Date: 2024-05-31
Effects of Ondansetron on Gastrointestinal Sensorimotor Dysfunctions in Diabetes Mellitus and Dyspepsia
CTID: NCT03865290
Phase: Phase 2    Status: Recruiting
Date: 2024-05-30
Comparative Efficacy of Dexamethasone - Ondansetron Versus Dexamethasone - Haloperidol in Reducing PONV
CTID: NCT06428084
Phase: Phase 2    Status: Completed
Date: 2024-05-24
A Proof of Principle Study of Ondansetron for the Prevention of Vasovagal Syncope: The Eleventh Prevention of Syncope Trial (POST11)
CTID: NCT05755737
Phase: Phase 2    Status: Recruiting
Date: 2024-05-10
Study of Ondansetron in the Prevention of Sleep Syncope: The Nineth Prevention of Syncope Trial (POST9)
CTID: NCT05657925
Phase: Phase 3    Status: Not yet recruiting
Date: 2024-05-09
Noninvasive Markers of Functional Nausea in Children
CTID: NCT03593811
Phase: N/A    Status: Enrolling by invitation
Date: 2024-05-09
Dexamethasone vs Ondansetron After Cesarean Delivery
CTID: NCT05692245
Phase: Phase 4    Status: Completed
Date: 2024-05-08
Effects of Ondansetron in Obsessive-compulsive and Tic Disorders
CTID: NCT03239210
Phase: Phase 4    Status: Completed
Date: 2024-05-03
The Efficacy of B6 and Metoclopramide Combination in Comparison With the Other Antiemetics
CTID: NCT06390787
Phase: Phase 2/Phase 3    Status: Completed
Date: 2024-04-30
Fasting Study of Ondansetron Tablets 24 mg and Zofran® Tablets 24 mg
CTID: NCT00649532
Phase: Phase 1    Status: Completed
Date: 2024-04-24
Food Study of Ondansetron Tablets 24 mg and Zofran® Tablets 24 mg
CTID: NCT00648583
Phase: Phase 1    Status: Completed
Date: 2024-04-24
Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC)
CTID: NCT03056482
Phase: Phase 4    Status: Completed
Date: 2024-04-03
Ondanstron Weekly vs Every 3 Weeks for Prevention of Nausea and Vomiting Induced by Chemotherapy Combined With PD-1 Blockade
CTID: NCT06080880
Phase: N/A    Status: Recruiting
Date: 2024-02-29
Designing Optimal Prevention and Management of Postoperative Nausea and Emesis for Patients Undergoing Laparoscopic Sleeve Gastrectomy
CTID: NCT03435003
Phase: Phase 4    Status: Completed
Date: 2024-02-14
Capsaicin Cream as an Adjunctive Therapy for Nausea and Vomiting of Pregnancy
CTID: NCT05098067
Phase: Phase 2    Status: Completed
Date: 2024-02-07
Palonosetron vs Ondansetron In PONV Prophylaxis Among Idiopathic Scoliosis Patients
CTID: NCT05956899
Phase: Phase 4    Status: Recruiting
Date: 2024-02-07
Ondansetron as a Strategy for Reducing Propofol Injection Pain in Pediatrics: a Randomized Controlled Trial
CTID: NCT05378113
Phase: Phase 2    Status: Recruiting
Date: 2024-01-11
The Ondansetron Premedication Trial in Juvenile Idiopathic Arthritis
CTID: NCT04169828
Phase: N/A    Status: Active, not recruiting
Date: 2024-01-09
PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers
CTID: NCT04209595
Phase: Phase 1/Phase 2    Status: Active, not recruiting
Date: 2024-01-03
Examining the Effect of Ondansetron on Bowel Prep Success
CTID: NCT05439772
Phase: Phase 4    Status: Completed
Date: 2023-12-20
Granisetron Versus Ondansetron for Nausea and Vomiting in Pediatric Age Group
CTID: NCT06175806
Phase: N/A    Status: Completed
Date: 2023-12-19
Haloperidol, Droperidol, Ondansetron in Cannabis Hyperemesis
CTID: NCT05065567
Phase: Phase 2    Status: Terminated
Date: 2023-11-28
Low Dose Aprepitant for Patients Receiving Carboplatin
CTID: NCT03237611
Phase: Phase 2    Status: Terminated
Date: 2023-11-13
Ondansetron for Postspinal Anesthesia Hypotension
CTID: NCT05475873
Phase: N/A    Status: Completed
Date: 2023-11-02
5-HT3 Receptor Antagonist and Respiratory Drive in Patients With ARDS
CTID: NCT05514483
Phase: Phase 4    Status: Recruiting
Date: 2023-09-28
Prophylaxis Against Postoperative Nausea and Vomiting After Laparoscopic Cholecystectomy
CTID: NCT06017167
Phase: Phase 2    Status: Recruiting
Date: 2023-08-30
Liver Fibrosis in Alpha-1 Antitrypsin Deficiency (Liver AATD)
CTID: NCT01810458
Phase:    Status: Completed
Date: 2023-08-21
TReatment of Irritable Bowel Syndrome With Diarrhoea Using Titrated ONdansetron Trial
CTID: NCT03555188
Phase: Phase 3    Status: Completed
Date: 2023-08-07
Continuous Infusion of First-Generation 5-HT3 Receptor Antagonists in Combination With Dexamethasone
CTID: NCT05872893
Phase: Phase 3    Status: Recruiting
Date: 2023-07-21
Rolapitant as an Antiemetic in Malignant Glioma Patients Receiving Radiotherapy and Temozolomide
CTID: NCT02991456
Phase: Phase 2    Status: Completed
Date: 2023-07-11
PROUD Study - Preventing Opioid Use Disorders
CTID: NCT04766996
Phase: Phase 4    Status: Terminated
Date: 2023-06-22
Antiemetic Prophylaxis With Fosaprepitant and Ondansetron in Patients Undergoing Thoracic Surgery
CTID: NCT05881486
Phase: N/A    Status: Not yet recruiting
Date: 2023-06-06
Haloperidol for the Treatment of Nausea and Vomiting in the ED
CTID: NCT04764344
Phase: Phase 4    Status: Completed
Date: 2023-06-01
Ondansetron for the Treatment of Heavy Drinking Among Emerging Adults
CTID: NCT00890149
Phase: Phase 2    Status: Terminated
Date: 2023-05-26
A Study of TAK-951 to Stop Adults Getting Nausea and Vomiting After Planned Surgery
CTID: NCT04557189
Phase: Phase 2    Status: Completed
Date: 2023-04-21
Pharmacogenetic Treatments for Alcoholism
CTID: NCT01591291
Phase: Phase 2/Phase 3    Status: Withdrawn
Date: 2023-04-20
Hyoscine Butyl-bromide Versus Ondansetron for Nausea and Vomiting During Cesarean Section Under Spinal Anesthesia
CTID: NCT04785118
Phase: Phase 4    Status: Completed
Date: 2023-03-16
Ondansetron and Blood Coagulation
CTID: NCT04499274
Phase: N/A    Status: Recruiting
Date: 2023-03-15
The Efficacy of Adjunctive Use of Ondansetron in Patients With Sepsis and Septic Shock
CTID: NCT05402553
Phase: Phase 1/Phase 2    Status: Recruiting
Date: 2023-03-15
Comparison of Postoperative Anti-nausea and Vomiting Effect Between Glycopyrronium and Ondansetron
CTID: NCT05265507
Phase: Phase 4 Sta
TReatment of Irritable bowel syndrome using Titrated ONdansetron Trial
CTID: null
Phase: Phase 3    Status: Completed
Date: 2017-11-07
The added effect of oral ondansetron to care-as-usual on persisting
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2017-01-23
The effect of oral ondansetron on referral rate in children aged 6 months to 6 years attending in primary care out of hours service with acute gastro-enteritis and vomiting.
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2015-09-07
A Phase III, Randomised, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of MK-0517/Fosaprepitant and Ondansetron Versus Ondansetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Paediatric Subjects Receiving Emetogenic Chemotherapy
CTID: null
Phase: Phase 3    Status: Completed
Date: 2015-08-05
Pharmacokinetics of Understudied Drugs Administered to Children per Standard of Care
CTID: null
Phase: Phase 1    Status: Not Authorised
Date: 2015-04-10
INTERET DE L’ONDANSETRON INTRAVEINEUX EN PREVENTION DES HYPOTENSIONS INDUITES PAR LA RACHIANESTHESIE POUR CESARIENNE : ETUDE MONOCENTRIQUE RANDOMISEE CONTROLEE EN DOUBLE AVEUGLE
CTID: null
Phase: Phase 3    Status: Prematurely Ended
Date: 2014-12-19
à compléter
CTID: null
Phase: Phase 3    Status: Completed
Date: 2013-07-09
Can 5-HT3 receptor antagonists be used to limit vomiting in rota- and norovirus infections?
CTID: null
Phase: Phase 2    Status: Completed
Date: 2013-01-07
A Phase IIb, Partially-Blinded, Randomized, Active Comparator-Controlled Study to Evaluate the Pharmacokinetics/Pharmacodynamics, Safety, and Tolerability of Aprepitant in Pediatric Patients for the Prevention of Post Operative Nausea and Vomiting
CTID: null
Phase: Phase 2    Status: Completed
Date: 2012-11-05
A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of Intravenous Fosaprepitant Dimeglumine for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With Moderately Emetogenic Chemotherapy
CTID: null
Phase: Phase 3    Status: Completed
Date: 2012-09-04
A Multicenter, Randomized, Single-blind, Active-controlled, Parallel Group, Phase II Study to Evaluate the Efficacy, Safety, and Tolerability of a Single Intravenous (6 mg, 12 mg, 18 mg, 24 mg or 36 mg) Dose of the Neurokinin-1 Receptor Antagonist, Vestipitant (GW597599), Compared with a Single 4 mg Intravenous Ondansetron Hydrochloride Dose for the Treatment of Breakthrough Post-Operative Nausea and Vomiting after Failed Prophylaxis with an Ondansetron-Containing Regimen in Patients Undergoing Non-Emergency Surgical Procedures
CTID: null
Phase: Phase 2    Status: Prematurely Ended
Date: 2012-04-05
A multicenter, randomized, double-blind, parallel group study to evaluate the efficacy and safety of two different doses of palonosetron compared to ondansetron in the prevention of CINV in pediatric patients undergoing single and repeated cycles of MEC or HEC.
CTID: null
Phase: Phase 3    Status: Ongoing, Completed
Date: 2011-08-04
ORAL ONDANSETRON VS DOMPERIDONE FOR SYMPTOMATIC TREATMENT OF VOMITING DURING ACUTE GASTROENTERITIS IN CHILDREN: MULTICENTRE RANDOMIZED CONTROLLED TRIAL
CTID: null
Phase: Phase 3    Status: Ongoing
Date: 2011-07-04
A Multicenter, Double-blind, Double-dummy, Randomized, Parallel Group, Stratified Study to Evaluate the Efficacy and Safety of a Single IV Dose of Palonosetron Compared to a Single IV Dose of Ondansetron to Prevent Postoperative Nausea and Vomiting in Pediatric Patients
CTID: null
Phase: Phase 3    Status: Completed
Date: 2011-05-23
Scottish and Newcastle Anti-emetic Pre-treatment for Paracetamol Poisoning study (SNAP)
CTID: null
Phase: Phase 4    Status: Completed
Date: 2010-04-01
Ondansetron for the treatment of IBS with diarrhoea (IBS-D): Identifying the “responder”
CTID: null
Phase: Phase 4    Status: Completed
Date: 2008-11-10
This protocol describes a total of three studies that are intrinsically linked. It does therefore have three titels.
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2008-11-07
” A comparative double-blind placebo-controlled study between alizapride and ondansetron for the prevention of postoperative nausea and vomiting.”
CTID: null
Phase: Phase 4    Status: Completed
Date: 2008-09-05
Ondansetronin vaikutus parasetamolin kipulääkevasteeseen tähystyksen kautta tehtävän kohdunpoiston yhteydessä
CTID: null
Phase: Phase 4    Status: Completed
Date: 2007-11-09
Activity of twice daily per os administration of CD06713 at 8mg versus its placebo during 4 weeks treatment, in patients with erythemato-telangiectatic rosacea.
CTID: null
Phase: Phase 2    Status: Completed
Date: 2007-01-09
Brush-evoked allodynia in patients with peripheral neuropathy before and following intravenous infusion of ondansetron. A randomised, double-blind, placebo controlled, cross-over study.
CTID: null
Phase: Phase 4    Status: Completed
Date: 2007-01-03
A Randomized, Double-Blind, Parallel-Group Study Conducted Under In-House Blinding Conditions to Determine the Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Moderately Emetogenic Chemotherapy (Study #2)
CTID: null
Phase: Phase 3    Status: Completed
Date: 2006-11-23
A Phase III Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel Group Study of the Efficacy and Safety of the Intravenous and Oral Formulations of the Neurokinin-1 Receptor Antagonist, Casopitant, administered in Combination with ZOFRAN and Dexamethasone for Prevention of Chemotherapy-Induced Nausea and Vomiting in Cancer Subjects Receiving Highly Emetogenic Cisplatin-Based Chemotherapy
CTID: null
Phase: Phase 3    Status: Completed
Date: 2006-09-11
A Phase III, Multicenter, Randomized, Double-Blind, Active Controlled, Parallel Group Study of the Safety and Efficacy of the Intravenous and Oral Formulations of the Neurokinin-1 Receptor Antagonist, Casopitant (GW679769) in Combination with Ondansetron and Dexamethasone for the Prevention of Nausea and Vomiting Induced By Moderately Emetogenic Chemotherapy
CTID: null
Phase: Phase 3    Status: Completed
Date: 2006-07-24
A Randomized, Double-Blind, Active Comparator-Controlled, Parallel-Group Study
CTID: null
Phase: Phase 3    Status: Prematurely Ended
Date: 2006-06-12
A Phase III, Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of 50 mg Oral Dosing with the Neurokinin-1 Receptor Antagonist GW679769 for the Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis
CTID: null
Phase: Phase 3    Status: Completed
Date: 2006-03-29
A Phase III Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of the 30 mg Intravenous Formulation of the Neurokinin-1 Receptor Antagonist GW679769 for Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis
CTID: null
Phase: Phase 3    Status: Completed
Date: 2006-03-20
Postoperative nausea and vomiting: acupuncture effect on postoperative prevention
CTID: null
Phase: Phase 4    Status: Completed
Date: 2006-01-05
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose-ranging, Parallel Group Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of the Oral Neurokinin-1 Receptor Antagonist, GW679769, When Administered with Intravenous Ondansetron Hydrochloride for the Prevention of Post-operative Nausea and Vomiting (PONV) and Post-discharge Nausea and Vomiting (PDNV) in Female Subjects
CTID: null
Phase: Phase 2    Status: Completed
Date: 2005-05-20
A Multicentre, Randomised, Double-blind, Double-dummy, Placebo-controlled, Parallel Group, Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Oral (25 mg) and Intravenous (3 mg and 18 mg) Formulations of the Neurokinin-1 Receptor Antagonist, GW597599, When Administered with Intravenous Ondansetron Hydrochloride for the Prevention of Post-operative Nausea and Vomiting and Post-discharge Nausea and Vomiting in Female Subjects with Known Risk Factors for PONV
CTID: null
Phase: Phase 2    Status: Completed
Date: 2005-02-08
A multicentre, randomised, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of oral dosing with GW679769 (50 mg or 150 mg) for 3 consecutive days in conjunction with a single intravenous dose of ondansetron for the prevention of post-operative and post-discharge nausea and vomiting in at risk females undergoing laparoscopic/laparotomic surgical procedures.
CTID: null
Phase: Phase 2    Status: Completed
Date: 2005-02-01

CTID: null
Phase: Phase 2    Status: Completed
Date: 2005-01-25
A Phase II Multicentre, Randomised, Double-Blind, Placebo and Active-Controlled, Dose-Ranging, Parallel Group Study of the Safety and Efficacy of The Oral Neurokinin-1 Receptor Antagonist, GW679769 When Administered at daily doses of 50 mg, 100 mg, and 150 mg Oral Tablets in Combination with Ondansetron Hydrochloride and Dexamethasone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Cancer Subjects Receiving Highly Emetogenic Cisplatin-based Chemotherapy.
CTID: null
Phase: Phase 2    Status: Completed
Date: 2005-01-25
Efficacité de l’ondansetron sur les vomissements dus aux gastroentérites aiguës pédiatriques en période hivernale
CTID: null
Phase: Phase 3    Status: Ongoing
Date:
Ramdomized phaseII trial of concurrent antiemetics with oral rehydration therapy for children with vomiting in the result of acute gastroentiritis
CTID: UMIN000001813
Phase: Phase II    Status: Recruiting
Date: 2009-03-30

Biological Data
  • Ondansetron
    Antagonism of the contractile response to 5-HT in the mouse ileum by granisetron, tropisetron, ondansetron and MDL 72222.Br J Pharmacol. 2000 Dec; 131(8): 1716–1722.
  • Ondansetron
    The ability of the 5-HT3 receptor selective antagonist, ondansetron, to inhibit the 5-HT-induced inward current in GI vagal afferent neurons is dependent upon extracellular glucose concentration.PLoS One.2011 Jan 28;6(1):e16519.
  • Ondansetron
    5-HT3A CNiFER: Ondansetron antagonism.Neurogastroenterol Motil.2012 Oct;24(10):e476
Contact Us